MedWatch

Blow for Eli Lilly as research institute deems diabetes candidate no better than competition

Eli Lilly’s type 2 diabetes candidate, tirzepatide, is no better than other diabetes drugs on the market, including Novo Nordisk’s blockbuster Ozempic, according to the Institute for Clinical and Economic Review.

Photo: Mike Segar/Reuters/Ritzau Scanpix

Eli Lilly’s tirzepatide – presumably the biggest competition for Novo Nordisk’s new generation of diabetes drugs – is not more effective than other type 2 diabetes treatments on the market.

This was the conclusion reached by experts from the Institute for Clinical and Economic Review (ICER), an independent US-based research institute that evaluates the efficacy of new drugs.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs